- All Records
- Pamphlet
- Adalimumab
- Adenosine - therapeutic use
Adalimumab therapy for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams35127
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program.
Halifax, NS:
Nova Scotia Health Authority
, 2022.
- Pamphlet Number
- 1207
- Available Online
- View Pamphlet
Your health care provider feels that treatment with adalimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2022
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (11 p.) : digital, PDF file
- Subjects (MeSH)
- Adalimumab
- Inflammatory Bowel Diseases - drug therapy
- Subjects (LCSH)
- Inflammatory bowel diseases
- Specialty
- Medications
- Abstract
- Your health care provider feels that treatment with adalimumab may help you manage your inflammatory bowel disease (IBD). This pamphlet describes what adalimumab is and some important aspects of therapy with this medication. Precautions and possible side effects are listed.
- Notes
- Previous title: Adalimumab (Humira) therapy
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 1207
Nova Scotia Health Authority. QEII. Cardiology.
Halifax, NS:
Nova Scotia Health Authority
, 2019.
- Pamphlet Number
- 1496
- Available Online
- View Pamphlet
Ticagrelor is a medicine used along with low dose Aspirin to reduce your risk of having a heart attack. You should not take Ticagrelor if you have or had a current bleeding problem such as bleeding from a stomach ulcer or if you have severe liver disease. Instructions for how to take and store this medicine as well as drug interactions and foods to avoid are discussed. Missed dose instructions are given. This pamphlet also describes warnings and possible side effects.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. QEII. Cardiology
- Alternate Title
- Brilinta
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2019
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document ([4] p.) : digital, PDF file
- Subjects (MeSH)
- Platelet Aggregation Inhibitors - therapeutic use
- Adenosine - therapeutic use
- Cardiovascular Diseases - prevention & control
- Myocardial Infarction - prevention & control
- Pulmonary Embolism - prevention & control
- Subjects (LCSH)
- Adenosine
- Anticoagulants (Medicine)
- Cardiovascular system--Diseases--Prevention
- Myocardial infarction--Prevention
- Abstract
- Ticagrelor is a medicine used along with low dose Aspirin to reduce your risk of having a heart attack. You should not take Ticagrelor if you have or had a current bleeding problem such as bleeding from a stomach ulcer or if you have severe liver disease. Instructions for how to take and store this medicine as well as drug interactions and foods to avoid are discussed. Missed dose instructions are given. This pamphlet also describes warnings and possible side effects.
- Responsibility
- Prepared by: Cardiology
- Pamphlet Number
- 1496
